The company can attribute its success to several strategic acquisitions that enhanced the core products offered by the company. The sale of the OP-1 product family allowed the company to refocus biologic research and development activities.
Stryker repurchased 6.1 million shares at a cost of $314 million during the fourth quarter. Domestic sales were reported as $1.286 billion during the fourth quarter, an 11 percent increase from last year. The international sales were $710 million, a 5 percent increase from last year.
Worldwide orthopedic implant sales were reported as $1.166 billion during the fourth quarter, a 4.5 percent increase from last year.
Read the Stryker release on the 4Q FY 2010 financial report.
Read other coverage on Stryker:
– Stryker Expands Its Board of Directors
– Stryker Sells OP-1 Products to Olympus Corp. for $60M
– Stryker Purchases Porex Surgical
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
